3 results
Approved WMOCompleted
Demonstrate an increase of 2-year overall survival (OS) of 15 % (from 50% to 65 %) vs historical controls of the addition of nitroglycerin to radiotherapy (±chemotherapy) of stage I-IV NSCLC.
Approved WMOWill not start
To investigate whether a treatment strategy offering bezlotoxumab before FMT in patients suffering from multiple recurrent CDI results in equal efficacy compared with a treatment strategy with initial FMT. Strategy A includes bezlotoxumab as…
Approved WMORecruiting
The current trial aims to demonstrate that sugammadex is generally safe and effective for reversing both moderate and deep block after rocuronium or vecuronium induced NMB in term neonates and young children.